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Abstract: To combat the coronaviruses and their novel variants, therapeutic drugs and the development of vaccines that are to be
effective throughout human life are urgently needed. The endocannabinoid system (ECS) acts as a modulator in the activation of the
microcirculation, immune system, and autonomic nervous system, along with controlling pharmacological functions such as emotional
responses, homeostasis, motor functions, cognition, and motivation. The ECS contains endogenous cannabinoids, cannabinoid
receptor (CBRs), and enzymes that regulate their biosynthesis, transport, and degradation. Moreover, phytocannabinoids and synthetic
cannabinoids that mimic the action of endocannabinoids also play an essential role in the modulation of the ECS. Cannabinoids, the
main constituents of cannabis (Cannabis sativa L.), are therapeutic compounds that have received international attention in the health
field due to their therapeutic properties. Recently, they have been tested for the treatment of COVID-19 due to their antiviral properties.
Indeed, cannabinoid-type compounds, and in particular cannabidiol (CBD), isolated from glandular trichomes found in the calyx
of cannabis flowers with reported antiviral properties is hypothesized to be a therapeutic option in the ministration of SARS-CoV-2
consorted with COVID-19 disease. The relevant articles were determined from the database search published mainly in Web of Science,
Google scholar, PubMed, Crossref, and ClinicalTrials.gov database during the pandemic period. The articles were evaluated for the
therapeutic potentials, mechanisms of action of cannabinoids, the roles of the ECS in the immune system, impact of cannabinoids in
SARS-CoV-2 septic, especially if they address the application of cannabinoids as drugs for the curability and management of SARSCoV-2 and its novel variants. Although the evidence needed to be considered using cannabinoids in the control and treatment of viral
diseases is currently in its infancy, they already offer an opportunity for clinicians due to their effects in relieving pain, improving
appetite, and improving childhood epilepsy, especially in cancer and human immunodeficiency virus (HIV/AIDS) patients. In addition
to these, the most recent scientific evidence emphasizes their use in the treatment of the coronavirus infected patients. In brief, all
preclinic and clinic studies that have been reported show that, through the cannabinoid system, cannabinoids, particularly CBD, have
many mechanisms that are effective in the treatment of patients infected by SARS-CoV-2. Thus, more extensive studies are necessary in
this area to fully identify the effects of cannabinoids on SARS-CoV-2.
Key words: Antiviral, cannabidiol, cannabinoids, cannabinoid system, COVID-19, SARS-CoV-2

1. Introduction
To date, seven different strains of coronavirus have been
identified to have infected humans (Liu et al., 2021). These
include HCoV-OC43 (OC43), HCoV-NL63 (NL63),
HCoV-HKU1 (HKU1), HCoV-229E (229E), Middle East
respiratory syndrome coronavirus (MERS-CoV), severe
acute respiratory syndrome coronavirus (SARS-CoV), and
SARS-CoV-2. Being an infectious disease, COVID-19 is

caused by human infection with SARS-CoV-2 (Desai and
Patel, 2020). It is usually characterized by inflammatory
response manifested by proinflammatory cytokine
production, overexpression of C-reactive protein (CRP),
neutrophil count, higher TNF, blood urea, and D-dimer
(Conti et al., 2020). Although not as bad as the flu epidemic
of 1918, COVID-19 has been the most devastating
pandemic among all other horrible outbreaks, such as
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pandemic influenza occured in 1957–1958 and 1968–1970,
swine flu in 2009, SARS in 2002–2004, and MERS in 2012,
2015 and 2018. Some human coronaviruses such as OC43,
229E, HKU1, and NL63 typically cause mild symptoms
including an upper tract of the respiratory system in adults
(Yang et al., 2020), while SARS-CoV-2, SARS-CoV, and
MERS-CoV cause infections in the lower respiratory tract
and give rise to bronchitis or pneumonia (Raj et al., 2021).
Among human coronaviruses, SARS-CoV-2, SARS-CoV,
and MERS-CoV often induce lung cell damage as these
coronaviruses develop evolutionarily drug resistance by
producing various proteins, which let them escape from
the immune system of the host (Molaei et al., 2020).
According to the latest data, this immune dysregulation
that develops as a result of the attacks of these proteins
on cells may be involved in an immunosuppression phase
following the pro-inflammatory (cytokine storm) phase,
accompanied by a high risk of secondary bacterial infection
and peripheral lymphopenia (Boechat et al., 2021).
Numerous studies have been and are being conducted
by large-scale investments and research institutions
by several governments to immunize or cure COVID
19. According to the WHO COVID-19 Dashboard1,
as of 2 July 2021, it had been reported that more than
182,319,261 million COVID-19 cases, with over 3,954,324
million deaths occurred globally. In order to prevent this
destruction faced by humanity, effective vaccines or drugs
are urgently needed for COVID-19. Effective antiviral drugs
have been developed as of May 15, 2021, and at least seven
different vaccines have already been launched worldwide2
and additionally at least 1653 listed vaccine candidates
are in development (https://www.who.int/emergencies/
diseases/novel-coronavirus-2019/covid-19 vaccines). As
of 1 July 2021, a total of 2,950,104,812 vaccine doses have
been administered. However, the only treatment currently
available for COVID-19 patients is supportive (Lucaciu
et al., 2021). The treatment options contain antimalarials,
antivirals, antibiotics, immunoglobulins, corticosteroids,
immunotherapy, anti granulocyte-macrophage colony
stimulating factor (anti-GM-CSF), interleukin-6 (IL-6)
inhibitors, convalescent, oxygen therapy, plasma, and
circulatory support (Lucaciu et al., 2021).
The currently applied vaccines aim to target SARSCoV-2 proteins rationally and specifically to suspend the
successive multiplication of the virus. However, extremely
infectious and globally spread variants such as P.1, B.1.351,
B.1.1.7, and B.1.617 of SARS-CoV-2 have been detected
in Brazil, South Africa, United Kingdom (UK), and India,
respectively (Burki, 2021). While vaccination is critical in
1
WHO (2021). Coronavirus Disease (COVID-19) Dashboard
[online]. Website https://covid19.who.int/ [accessed 2 July 2021]

WHO (2021). World health organization/news Dashboard [online].
Website https://www.who.int/news [accessed 15 May 2021]
2

preventing severe illness and death, and controlling the
pandemic, there are still uncertainties as to how effective
current vaccines will be in controlling the pandemic
and preventing subsequent deaths. As stressed above,
approximately over the last two decades, we have observed
at least three severe respiratory illnesses (COVID-19,
MERS, and SARS). As coronaviruses evolved from batto-human to human coronavirus disease, coronaviruses
might potentially reappear in the short run in the form of
epidemics or pandemics owing to their capacity to mutate,
infect and recombine their different host mechanisms
(El-Sayed and Kamel, 2021). While some of the
treatments applied are promising, they may also induce
many negative side effects such as hypertriglyceridemia
and pancreatitis (Morrison et al., 2020). Therefore,
it is imperative to discover alternative strategies for
effective treatment. One possible strategy is to identify
cannabinoids that exhibit beneficial anti-inflammatory
and immune-suppressive effects in preclinical models
of various chronic inflammatory diseases through the
activation of the cannabinoid system and to gain a deep
understanding of their mechanisms. Thus, by inhibiting
the replication processes of the coronavirus, there is
a chance to develop an effective therapeutic strategy.
Although the components and structural organization of
human ECS and the mechanism of action of its on SARSCoV-2 have been extensively studied, research in this area
is progressing rapidly.
As is emphasized in this review, there are many lessons
to be learned from studies on the effects of cannabinoids
on the immune system in SARS-CoV-2 infection via the
ECS. Therefore, the goal of this review is to update the
effect and mechanism of cannabinoids in the ECS and
their applications as medicines for the management of
SARS-CoV-2 in preclinical and clinical studies. These
include types of cannabinoids that affect the ECS as antiinflammatory agents, the ECS, and the roles of the ECS
in immunity. The review provides a summary of the
interaction of cannabinoids with viral diseases, especially
SARS CoV-2, the impacts of cannabinoids in SARS-CoV-2
infection, as well as preclinical and clinical evidence of
cannabinoid efficacy, and ends with the identification of
knowledge gaps.
2. Methodology
The literature search was comprehensively carried out in
search engines such as Google scholar, Web of Science,
PubMed, Crossref, and ClinicalTrials.gov database to
identify pertinent research articles on COVID-19. Until
21 May 2021, the keywords such as “cannabinoids”,
“cannabidiol”, “CBD”, “endocannabinoid system”,
“coronavirus”, “SARS-CoV-2 “,” new variants of the SARSCoV-2”, “COVID-19” were used to solely find the most
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relevant articles. In general, the most relevant and detailed
articles were reviewed, which included information on
cannabinoids, cannabinoids as anti-inflammatory agents,
the ECS, the role of ECS in the immune system, impact
of cannabinoids in SARS-CoV-2 infection, and preclinical
and clinic application of cannabinoids as medicines for
the control and management of SARS-CoV-2. C. sativa L.
(hemp or marihuana) is an obligate short-day flowering
plant species belonging to the Cannabaceae family and
has been used by different cultures for a wide variety of
medicinal, psychotropic, and industrial applications for
thousands of years (Li, 1974). Natural cannabidiol (CBD)
is produced from the glandular trichomes of the cannabis
plants. Hemp refers to cannabis plants or materials that
contain 0.2% (in the European Union Countries) and 0.3%
(in the USA) or less Δ9-tetrahydrocannabinol (Δ9-THC or
simply THC) content, and a relatively high CBD content
by dry weight (Small, 1979). In contrast, marijuana or
marihuana might be used in place of C. sativa plants or
materials that contain more than 0.3% THC in its dry
weight. Cannabis strains with higher CBD, THC or
cannabigerol (CBG) content can be bred, depending on
the type of cannabinoid to be produced. Figure 1A presents
flowering hermaphrodite hemp plants, whereas Figure
1B presents trichome development on the juvenile calyx
and Figure 1C mature calyx of female plant inflorescence,
respectively.
3. Results and discussion
3.1. Cannabis L. and Cannabinoids
C. sativa L. is arguably the world’s oldest drug, which
has medicinally been used for many millennia in Asian

countries since ancient times (Li, 1974). As many as 550
metabolites have already been identified in different
strains of Cannabis L., including cannabinoids (~150)
and >400 non-cannabinoid compounds such as terpenes,
hydrocarbons, sugars, nitrogenous compounds, flavonoids,
steroids, and amino acids (Paland et al., 2021; Schlag et al.,
2021). In addition to a myriad of secondary metabolites, a
naturally occurring metabolite, cannabinoids, which have
not been detected yet in other plants, are present in the
trichomes growing in the leaves and calyxes of C. sativa
plants (see Figures 1A–1C). Cannabinoids are defined as
lipophilic substances acting as ligands for specific types
of membrane receptors [commonly called cannabinoid
receptor 1 (CB1) and cannabinoid receptor 2 (CB2)]
(Sledzinski et al., 2021). Furthermore, these receptors are
related to the GPCR (G-protein-coupled receptor) family
and form part of the endocannabinoid system.
3.2. Types of cannabinoids as anti-inflammatory agents
Cannabinoids are a group of biologically active compounds
that have the potential to activate the CB1 found largely
and CB2 cannabinoid receptors in the body (Nagarkatti
et al., 2020). There are three main types of cannabinoids
that affect the ECS: (1) phytocannabinoids, (2) drugs
containing synthetic or natural cannabinoids, and (3)
endocannabinoids (i.e. anandamide) in animal or human
(Pertwee et al., 2010; Apostu et al., 2019; Petrescu et al.,
2020).
3.2.1. Phytocannabinoids
Phytocannabinoids are naturally present in the cannabis
plant. Of more than 150 different cannabinoids reported in
cannabis (Schlag et al., 2021), being the main psychoactive
ingredient of cannabis, THC was first isolated by

Figure 1. (A) Flowering hermaphrodite hemp plants and (B) glandular trichomes on juvenile or (C) swollen calyx or seeds.
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Gaoni and Mechoulam (1964), allowing new studies to
investigate cannabinoids from multiple perspectives.
Being a non-psychoactive compound, CBD is the
next most abundant phytocannabinoid to be found in
Cannabis (Mechoulam et al., 2007). The other extensively
studied phytocannabinoids are CBG, cannabinol (CBN),
cannabichromene (CBC), Δ9-tetrahydrocannabivarin (Δ9THCV or THCV), and cannabidivarin (CBDV). Among
the known phytocannabinoids, THC, CBN, CBG, and
THCV are the primary psychoactive cannabinoids. They
mimic by binding to small molecular receptor molecules
embedded in the membranous surfaces of functionally
similar molecule cells of the human body (Pertwee et al.,
2010). The use of high levels of THC or other psychoactive
cannabinoids for recreational or therapeutic purposes
creates a state of euphoria as well as anti-inflammatory
and analgesic effects, so the medical use of cannabinoids
with psychoactive properties has been limited (Dujourdy
and Besacier, 2017). The non-psychoactive cannabinoids
found in cannabis are CBD, CBC, CBDV, and CBG. While
these show low affinity for cannabinoid receptors, they are
known to interact with other receptors such as peroxisome
proliferator-activated receptors (PPARs, particularly
PPARα and PPARγ), the transient receptor potential
cation channel subfamily V member 1 (TRPV1), and the
orphan G protein-coupled receptors (GPR55, GPR119)
(Sledzinski et al., 2021).
Many cannabinoids, particularly CBD, have been
proven to act as powerful anti-inflammatory agents in
recent studies (Almogi-Hazan and Or, 2020; Nagarkatti et
al., 2020; Lima et al., 2021; Nguyen et al., 2021). The Food
and Drug Administration (FDA) has approved cannabidiol
(Epidiolex) and three synthetic drugs: Cesamet (nabilone),
Marinol (dronabinol), and Syndros (dronabinol).
Epidiolex consists of a purified form of hemp-derived CBD
used to treat patients with seizures correlated to Dravet or
Lennox-Gastaut syndromes in patients one year of age and
older (Nagarkatti et al., 2020). Most recently, CBD and
7-OH-CBD (a more active metabolite than CBD) have
been proposed as potential therapeutic and preventive
agents in the early stage of infection with SARS-CoV-2
(Nguyen et al., 2021). CBD, the most studied cannabinoid,
might also inhibit the production of proinflammatory
cytokines such as interferon gamma, tumor necrosis
factor alpha (TNF-α), inducible protein-10-interleukin IL2, IL-1α and β, IL-6, monocyte chemoattractant protein1α, macrophage inflammatory protein-1α (Nichols and
Kaplan, 2020). Another cannabinoid that has been studied
extensively, THC slows proinflammatory IL-17 secretion
and proliferation of activated lymphocytes and may
increase anti-inflammatory IL-10 secretion (Khuja et al.,
2018). In addition, in cell experiments investigating the
effect of THC on antibody formation, it has been shown

to induce immunosuppression in B cells (Eisenstein et
al., 2007). In many animal model studies, THC lessened
signaling proteins such as interferon-gamma (IFN-g) and
IFN-α pro-inflammatory cytokines (Rossi et al., 2020;
Mohammed et al., 2020). Studies have reported that the
reduction of TNF-α level occurs as a result of activation
of CB1 and CB2 receptors (Nichols and Kaplan, 2020;
Costiniuk and Jenabian, 2020). Moreover, CBG is a
precursor molecule for major phytocannabinoids such as
THC and CBD. CBG has been shown to have therapeutic
potential in the treatment of inflammatory bowel
disease, Huntington’s disease, neurological disorders
such as Parkinson’s disease, Alzheimer’s disease, multiple
sclerosis, and epilepsy (Nachnani et al., 2021). Overall,
phytocannabinoids have the potential to suppress cytokine
storm by acting on cells in different systems in different
ways through the endocannabinoid system to suppress
inflammation.
3.2.2. Drugs and synthetic cannabinoids
FDA approved one cannabis-derived drug that contains
natural cannabinoids such as THC and/or cannabidiol
represented by Epidiolex or Sativex (Apostu et al., 2019).
Since the discovery of THC in 1964, and the recognition of
cannabinoids’ therapeutic potential, extensive research has
been carried out to produce synthetic cannabinoids (SCBs)
that mimic the effects of natural THC (Mills et al., 2015).
SCBs, cannabinoid receptor ligands produced by chemical
synthesis, have a large family of molecules that mimic the
functions of natural cannabinoids. They are used in studies
aimed at determining the relationships between the
structure and activities of cannabinoids and for therapeutic
purposes in medicine, as well as for recreational purposes
(Lauritsen and Rosenberg, 2016). They include SR144528,
WIN-55,212-2, HU-331, HU-210, JWH-018, JWH-133,
and UR-144, but more than 140 are classified in this
group (Almada et al., 2020). They are available under four
groups: fatty acid amides, aminoalkylindoles, classical
cannabinoids, and non-classical cannabinoids (Cohen and
Weinstein, 2018). Such analogous cannabinoids are also
referred to as cannabimimetic cannabinoids and synthetic
cannabinoids. Synthetic cannabinoids, both drunk and
eaten, have been commercially marketed for many years.
The synthetic cannabinoids that are easily accessible
commercially today are as follows: Syndros (dronabinol),
Marinol, (Dronabinol), Cesamet (nabilone), Rimonabant,
and Zimulti (Apostu et al., 2019). However, the increase
in recreational use of SCBs and their therapeutic use
may result in tachycardia, breathing disorders, and
seizures (Almada et al., 2020). Of the SCBs currently
marketed, nabilone is a THC analogue, and dronabinol
is a biochemically identical form of THC. Both can be
prescribed clinically (Ebbert et al., 2018). By activating
CB1 or CB2 receptors, these cannabinoids modulate
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systems such as the central nervous system, immune,
cardiovascular, pulmonary, musculoskeletal, and digestive
systems (Apostu et al., 2019).
3.3. Endocannabinoid system
The ECS consists of cannabinoid receptors (CBRs),
endogenous cannabinoids, and enzymes that take part
in their biosynthesis, transport, and degradation (Lu and
Mackie, 2016). This system is involved in all of the human
body’s internal interactions, including the components
of the immune system such as antibodies, white blood
cells, the spleen, the thymus, the bone marrow, and the
lymphatic system (Apostu et al., 2019).
A summary of the disorders, including viral infections,
cancer, and other diseases that are thought to support
the treatment of cannabinoids through the cannabinoid
system is given in Figure 2 (Sledzinski et al., 2021).
Noticeable changes in the ECS activity have been
monitored in pathological conditions including
neurological disorders, cancers, and other diseases such
as mood/behavior, pain/insomnia, and gastrointestinal

disorders (Soliman, et al., 2021; Sledzinski et al., 2021).
Therefore, today pharmaceutical modulation of the ECS
has been an effective therapeutic strategy, for example
by the administration of cannabinoids in the treatment
of palliative care and weight loss (Sledzinski et al.,
2021). Additionally, the effect of cannabinoid uptake on
infectious conditions has been questioned for several
years due to its involvement in the immune function of
the endocannabinoid system but is of particular interest
today in the COVID 19 pandemic (El Biali et al., 2020).
Three main component groups have been identified in the
modulation of the ECS in the human brain.
3.4. Endocannabinoids (endogenous cannabinoids)
So far, in mouse and human model studies, at least
two main endocannabinoids (eCBs), 2-Arachidonyl
Glycerol (2-AG) (Devane et al., 1992) and N-arachidonyl
ethanolamine (Anandamide, AEA) have been identified
(Stella et al., 1997). They are metabolized very rapidly
by enzymes such as monoacylglycerol lipase (MAGL)
and fatty acid amide hydrolase (FAAH) for 2-AG

Figure 2. The involvement of the endocannabinoid system in various modulating processes makes it a promising target in the treatment
of several disorders including viral infections (Sledzinski et al., 2021).
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and anandamide (AEA), respectively (Shamran et al.,
2017). They are responsible for providing signaling with
cannabinoid receptors (Iannotti and Vitale, 2021). The
degradation pathways and synthesis of AEA and 2-AG
are almost completely different; although both are derived
from arachidonic acid, different enzymes mediate their
synthesis (Sledzinski, 2021). Different biosynthesis
methods have been described for the synthesis of AEA;
hydrolysis of NAPE (N-acylphosphatidylethanolamine)
with NAPE selective phospholipase D is the most known
biosynthesis method (Kumar et al., 2019). Elevated levels of
2-AG and AEA are especially found in the corpus striatum
and brainstem (Greenberg, 2003). In addition to these
two main cannabinoids, four putative endocannabinoid
ligands, (1) O-arachidonoyl ethanolamine (virodhamine)
(Porter et al., 2002), (2) noladin ether (2-arachidonoyl
glyceryl ether, 2-AGE) (Hanus et al., 2001), (3) NADA
(N-arachidonoyl dopamine) (Huang et al., 2002) and (4)
oleic acid amide (oleamide, OA) (Laezza et al., 2020) have
also been identified. Excessive alcohol use can trigger
the overproduction of endocannabinoids and affect
cardiovascular function by CB1 receptor signaling (Paloczi
et al., 2019). The neutral arachidonate derivative, 2-AG is
one of the main sources of arachidonic acid in the synthesis
of prostaglandins and plays a role in the metabolism
of lipids (Baggelaar et al., 2018). Brain prostaglandins
that promote neuroinflammation are formed as a result
of hydrolysis of endocannabinoids (Nomura et al.,
2011). Nevertheless, hydrolysis of 2-arachidonic acid by
phospholipase C (PLC) and diacylglycerol lipase α or β
(DAGL α or DAGL β) produces 2-AG (Kumar et al., 2019).
3.5. Cannabinoid receptors
G-protein-coupled receptors (GPCRs) and transient
receptor potential channels (TRPs ), which are embedded in
the cell membrane, have been determined as cannabinoid

receptors (Paland et al., 2021; Rohbeck et al., 2021). The
receptors CB1, CB2, GPCR18, and GPCR55 are members
of the GPCRs family (Almogi-Hazan and Or, 2020). The
human body has thousands of GPCRs. These include
dopamine, opioid, serotonin, and adrenergic receptors
(Small, 1979). TRPV1-4, TRPA1, and TRPM8 are TRPs
that are supposed to be cannabinoid receptors (Storozhuk
and Zholos, 2018). TRP channels regulate numerous
neural signaling processes and physiological roles such as
smell, pain perception, taste, vision, temperature sensation,
or pressure sensing (Moran et al., 2011). Molecules
binding to cellular receptors are chemically called ligands.
Pharmacologically, agonists are defined as the chemicals
that contact and activate receptors (Pertwee, 2010). Both
AEA and 2-AG are agonists at CB2 and CB1 receptors. In
general, many antagonists show high selectivity for the
CB1 receptor, allowing differentiation between CB1 and
CB2, while a large number of agonists show low selectivity
between cannabinoid receptors. However, some agonists,
such as the arachidonyl-20-chloroethylamide compound,
show high selectivity to CB1 (Howlett and Abood, 2017).
Moreover, the ligand (molecules that bind to cellular
receptors) selectivity, crystal structures, and functions of
these receptors have recently been determined (Li et al.,
2019).
Cannabinoid receptors are the most common type
of GPCR in the brain. The CB1 receptor is expressed
predominantly in the central nervous system (CNS)
and various non-neural peripheral tissues, including the
intestine and vasculature, particularly in neuromodulatory
roles, whereas the CB2 receptors that are expressed in
the spleen and lymph nodes are known for modulating
the immune response and inflammation (Rossi et al.,
2021; Lucaciu et al., 2021; Figure 3). CB2 receptors in the
immune system’s cells are present in T4 lymphocytes, B

Figure 3. Cannabinoid receptors in immune cells (Lucaciu et al., 2021).
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lymphocytes, leukocytes, T8 lymphocytes, macrophages,
mononuclear cells, microglia, mast cells, natural killer
cells, and in several organs and tissues such as the brain,
liver, spleen, tonsils or lymph nodes, thymus, lung, kidney
(Cabral and Griffin-Thomas, 2009; Rossi et al., 2020).
It is known that stimulation of CB2 receptors improves
the immune-modulating properties of mesenchymal
stromal cells, limits the release of proinflammatory
cytokines, and shifts the macrophage phenotype to the
anti-inflammatory M2 type (Rossi et al., 2020). Because of
these known functions and as shown in Figure 4, the CB2
receptor should be a therapeutic target in the emergency
of the COVID-19 pandemic. Instead, CB1, immensely
correlated to the psychoactive effects of cannabinoids, is
expressed at low levels in peripheral tissues and mostly in
the central nervous system (Farquhar-Smith et al., 2000;
Rossi et al., 2020).
In addition to CB2 and CB1 receptors, the ECS
has also been described to modulate a large number
of candidate receptors (they may be named as CB3
receptor) and channels with the inclusion of sundry
TRP (transient receptor potential) channels, GPCR

channels such as G-GPR55, a receptor linked with seven
transmembrane G proteins, GPR119, GPR18, glycine
receptors, -aminobutyric acid (GABA) A, and peroxisome
proliferator activated receptors (PPARs) such as PPAR-β
/δ, PPAR-γ and PPAR-α or transient receptor potential
vanilloid 1 (TRPV1) (Apostu et al., 2019; Ghaffari et al.,
2020). Among the CB3 candidates, GPR55 has gained much
attention for its activation by cannabinoids and its ability
to activate the immune system (Yang et al., 2016; Lucaciu
et al., 2021). Some phytocannabinoids, particularly THC,
mediate their biological effects primarily through CB2
and CB1 receptors. THC might act as an agonist of the
channels/receptors GPR18, GPR55, transient TRPV4,
TRPV3, TRPV2, TRPA1, PPAR, and as an antagonist of
the channels/receptors 5-HT3A and TRPM8 (Martinez
et al., 2020). However, CBD may act as an agonist of
adenosine channels/receptors TRPV3, TRPV2, TRPV1,
TRPA1, PPAR, 5-HT1A, A1, and A2 adenosine, and as
an antagonist of 5-HT3A, GPR18, and GPR55 receptors
(Burstein, 2015; Olah et al., 2017). In addition, CBD raises
AEA levels and is an inverse agonist of the GPR12, GPR6,
and GPR3 receptors.

Figure 4. The effect of cannabinoids on the immune system in SARS-CoV-2 infection. A. Structure features of SARS-CoV-2 and its
main SARS-CoV-2 Mpro binding pocket, B. SARS-CoV-2 life cycle in host lung cells is initiated by binding of ACE2 cellular receptor to
viral spike glycoprotein (Raj et al., 2021).
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3.6. Endocannabinoid enzymes
The enzymes responsible for the inactivation of
endocannabinoids (2-AG and AEA) are fatty acid amide
hydrolase (FAAH) inhibitors and MAGL, respectively
(Egmond et al., 2021).
MAGL and FAAH might implement therapeutic
effects without causing unpleasant side effects correlated
with direct CB1 receptor stimulation by THC (Egmond
et al., 2021). Palmitoyl and oleoyl ethanolamide are some
of the many fatty acid amides on which FAAH has a
catabolic effect (Mastinu et al., 2018). Therefore, natural or
many synthetic molecules that inhibit FAAH can generate
biological responses that are not limited to ECS (Kumar, et
al., 2019). Endocannabinoids can also undergo oxidative
metabolism by cytochrome P450 (Snider et al., 2010),
lipoxygenases (Kozak et al., 2002), and cyclooxygenases
(COX-2) (Kozak et al., 2000), forming new molecules
such as prostamides with potential physiological roles
(Alhouayek and Muccioli, 2014). Moreover, alpha/beta
domain hydrolases 6 and 12 (ABHD 6 and 12) and COX-2
might also play a role in the catabolism of 2-AG.
3.7. The roles of the ECS in immunity
The ECS has anti-inflammatory activities in adaptive and
innate immunity (Paland et al., 2021). In general, the ECS
functions in many systems in the human body, including
the musculoskeletal system, central nervous system,
immune system, and gastrointestinal system (Lucaciu et
al., 2021). The immune system is defined as a complex
system of protein and cell networks, all connected and
working together to fight infections. The ECS plays a
role in mature immune cell monitoring and regulation of
effector cell functions (Almogi-Hazan and Or, 2020). B
cells, T cells, macrophages, basophils, dendritic cells, mast
cells, eosinophils, neutrophils, natural killer cells, natural
killer T cells, CD8+ cells, and CD4+ cells are examples of
immune system cell types (Figure 2; Lucaciu et al., 2021;
Nichols and Kaplan, 2020). Like most cell types in the
human body, immune cells also produce cannabinoids
called endocannabinoids. These are endogenous ligands
for CB1 and CB2 receptors derived from arachidonic acid
(Nagarkatti et al., 2020). The response and effects of the
immune system take place through signal proteins, i.e.
antibodies, which are expressed or secreted proteins called
chemokines or cytokines (Nichols and Kaplan, 2020). CB2
deficiency, one of the cannabinoid receptors present in
immune cells, as well as in the entire immune system, has
been reported to increase acute neutrophil mobilization in
areas of inflammation (Kapellos et al., 2019). It has been
reported that monocytes/macrophages and microglial cells
express CB1 and CB2 receptors in both animals and cellulo
models of inflammatory diseases (Turcotte et al., 2016).
The role of CB2 in the retention of immature B cells in
the bone marrow has been proven by Pereira et al. (2009).

In addition, ECS also plays a much more direct role in
regulating adaptive immunity, the effect of which is longlasting. For example, in the experimental autoimmune
encephalomyelitis model, CB2-deficient T cells in the
central nervous system showed a high proliferation
rate, a decreased level of apoptosis, and an increase in
inflammatory cytokine production, resulting in severe
clinical disease (Maresz et al., 2007). Therefore, a research
group has shown that stimulating the immune system is a
good approach to prevent viral infections in patients with
severe flu (Hui et al., 2018). A recent article has reported
that immune system activation by the endocannabinoid
system has reduced or stopped viral replications, showing
a reduction in virus entry and leading to a reduction in
proinflammatory cytokines such as TNFα or IFNg, IL2, IL-4, IL-6, IL-12 (Lucaciu et al., 2021). A combined
therapeutic approach has been suggested to prevent host
overreaction to the invasion of SARS CoV-2 (Lucaciu et
al., 2021), which is associated with an overreaction of the
immune system and a cytokine storm (Tay et al., 2020). It
has also been reported that, with respect to SARS-CoV-2
infection, cannabinoids in the immune system have the
potential to reduce the mortality rate by limiting the
abnormal functions of the immune system (Lucaciu et al.,
2021).
The fact that cannabinoid receptors are expressed
by immune cells and that these receptor agonists show
strong anti-inflammatory activity aiming at cannabinoid
receptors demonstrates that the endocannabinoid system
is an important regulator of the immune system. Thus, all
these studies indicate the need for more intensive research
on endocannabinoids as a new approach to the treatment
of systemic inflammation, cytokine storm, and acute
respiratory distress syndrome (ARDS) in patients with
COVID (Nagarkatti et al., 2020).
3.8. Cannabinoids and viral illnesses
A viral infection develops as a result of contention
between the organism’s adaptive and innate immune
system response and the infectious potential of the virus
(Sledzinski et al., 2021). The agonists of CB1 receptor
such as endocannabinoids can inhibit Ca2+ ions release,
affecting activation of Ca2+-dependent proteins and
changing signal transduction (Zou and Kumar, 2018).
Malfunction of numerous Ca2+ dependent enzyme
structures, such as transglutaminases or calpains and
matrix metalloproteinases involved in inflammatory
processes, can promote virus replication (Reiss, 2010).
Several studies have been reported on the antiviral effect
of CBD due to its anti-inflammatory properties. Although
the antiviral effect of CBD is effective for the treatment of
viral hepatitis (Lowe et al., 2017), or influenza (Karmous
et al., 2013), HIV (Costiniuk et al., 2019), borna disease
virus or vaccinia virus (Tahamtan et al., 2016) and
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orthopoxvirus, studies on the use of cannabinoids in
treating viral diseases caused by all forms of coronavirus,
including SARS-CoV-2, are still in their infancy.
In a viral multiple sclerosis model, Nabiximoles
improved motor activity as measured by the presence of
microglial activity, axonal damage and central nervous
system infiltrates, while renovating myelin morphology in
a multiple sclerosis viral model (Feliu et al., 2015). In a study
of patients living with HIV, cannabis exposure was found
to cause lower neurocognitive impairments (Watson et al.,
2020). As an antiviral agent, CBD has been shown to have
no effect against hepatitis B virus cultured to produce these
viruses in cell lines but an antiviral effect against hepatitis
C virus (HCV) (Lowe et al., 2017). In another study using a
CSHV-infected human dermal microvascular endothelial
cell model, CBD has been shown to have an indirect viral
effect against Kaposi’s sarcoma-associated herpesvirus
(KSHV) (Maor et al., 2012). In another study, CBD was
shown to attenuate the effects of neuroinflammation
caused by Theiler’s murine encephalomyelitis virus
(TMEV) (Mecha et al., 2013). In both HIV and post-Ebola
syndrome, CBD has been suggested as a therapeutic agent
to control the activation of the immune system (Costiniuk
et al., 2019). Dronabinol or THC is approved for the
management or treatment of vomiting and weight loss in
human immunodeficiency virus (HIV)/acquired immune
deficiency syndrome (AIDS) and cancer (Badowski and
Yanful, 2018). A recently published study suggested that
the antiviral potential of CBD and THC against SARSCoV-2 is more effective than CBDA, THCA, and CBN, but
there may be safety concerns for humans as high doses of
CBD or THC cause cytotoxicity in the host cell (Raj et al.,
2021).
3.9. Impact of cannabinoids in SARS-CoV-2 infection
COVID-19 is usually characterized by inflammatory
response manifested by pro-inflammatory cytokines
production (IL-1, IL-6, IL-10), overexpression of C-reactive
protein (CRP), neutrophil count, higher TNF, blood urea,
and D-dimer (Conti et al., 2020). The spike proteins of the
virus bind to ACE2 (angiotensin converting enzyme 2)
receptors on the surface of the cell or TMPRSS2-mediated
membrane fusion upon ACE2 engagement, and release
viral RNA into the cell via endocytosis (Bian and Li, 2021).
According to a recent study (Gadanec et al., 2021), ACE2free intra- and extrapulmonary immune and non-immune
cells also demonstrated viral susceptibility. This suggests
that the S protein also utilizes toll-like receptors (TLR),
C-lectin-type receptors (CLR), the non-immune receptor
glucose-regulated protein 78 (GRP78), and neuropilin-1
(NRP1).
Cannabinoids have the potential to inhibit the
secretion of many pro-inflammatory cytokines resulting
in the prevention of cytokine release syndromes (CRS)
(Paland et al., 2021). Very recently, Raj et al. (2021)
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reported a preliminary effort to discover dual-acting
phytocannabinoids capable of interacting with CB2
receptors in the lungs (agonist) and SARS-CoV-2 Mpro as
an antagonist. In their computational and in vitro based
study, it has been suggested that both CBD and THC can
inhibit SARS-CoV-2 in two ways (Raj et al., 2021). They
can bind to and inhibit SARS-CoV-2Mpro by blocking
translation; they also act as agonists of the CB2 receptor,
reducing pro-inflammatory cytokine levels in lung cells
(Figure 4; Raj et al., 2021). The SARS-CoV-2 genome
encodes several proteins (already identified 25 proteins)
that the virus needs to infect humans and replicate itself
(Parks and Smith, 2020). Among these, SARS-CoV-2Mpro,
the glycoprotein (S), notorious spike (S) protein, which
recognizes human ACE2 in the initial stage of infection,
chymotrypsin-like main protease, papain-like protease,
the RNA polymerase, which synthesizes viral RNA, two
proteases, which cleave viral and human proteins, and
the RNA-cleaving endoribonuclease are known to play an
important role in the progress of SARS-CoV-2 (Parks and
Smith, 2020).
The SARS-CoV-2 life cycle is initiated by binding
between the S-protein of SARS-CoV-2 and ACE2 (cellular
receptor), a protein with an enzymatically active site
on the surface of cells in host lung cells or other organ
tissues (Han and Kral, 2020; Zhang et al., 2020a). Spike
glycoprotein (S-protein) mediates viral envelope fusion
with host cells via endosomal pathways. As a result of the
occurring fusion, the viral cell releases the RNA of SARSCoV-2 into the host cell and converts the viral genome
RNA into replicase polyproteins 1ab and pp1a. These
proteins are cleaved into small products by proteinases
(Romano et al., 2020; Shereen et al. 2020; See Figure 4).
Papain-like protease and SARS-CoV-2 Mpro are essential
for the processing of polyproteins (Zhang et al., 2020b).
Later, a sequence of sub-genomic mRNA is formed by
the polymerase (Hu et al., 2020). Also, viral proteins and
genome RNA are accumulated into virons in the ER and
Golgi, and SARS-CoV-2 is transported in vesicles to the
extracellular compartment (Raj et al., 2021). During this
process, M1 pro-inflammatory macrophages and T-helper
cells secrete interleukins released from macrophages and
T-lymphocytes, which cause extensive inflammation
inside lung cells (Vabret et al., 2020). At this stage, the
CB2 receptor activated by CBD administration inhibits
inflammatory processes such as macrophage migration into
the lungs (Pisanti et al., 2017; Hernandez-Cervantes et al.,
2017) and sets therapeutic targets for the reduction of some
other immune pathological processes associated with viral
infections (Costiniuk and Jenabian, 2020). However, more
M2 phenotype macrophages are produced by inhibition of
the CB2 receptor, thus causing the production of IL-10 and
anti-inflammatory TGF-b (Rossi et al., 2020). Responding
to infection with an aggressive inflammatory reaction,
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the host’s airways are damaged (Wong et al. 2004). As
a result, a vast cytokine release occurs by the immune
system, causing a cytokine storm associated with typical
sepsis symptoms such as breathing problems, abnormal
heart function, low platelet count, unconsciousness, and
tremors, many of which are associated with fatal COVID
cases (Onaivi and Sharma, 2020). Moreover, uncontrolled
inflammation affects multiple organs, leading to cardiac,
hepatic or renal failures (Lucaciu et al., 2021).
Discovering drugs that can bind to viral proteins and
prevent them from working is a logical route forward
and should be a priority for many research laboratories
(Parks and Smith, 2020). As SARS-CoV-2 Mpro inhibition
is unlikely to induce any toxic effects on humans, it is
considered the best molecular target for inhibition of
coronavirus replication (Zhang et al., 2020a; Al-Khafaji
et al., 2020; Abian et al., 2020). As explained in Figure 4
above, by acting as agonists of the CB2 receptor, CBDs have
been demonstrated to inhibit SARS-CoV-2 Mpro activity
and block viral replication due to their binding affinity,
complex stability, and in vitro potency (Raj et al., 2021).
More importantly, such inhibitors (inhibitor for SARS
CoV-2 Mpro) are unlikely to be toxic, and human protease
similar to SARS-CoV-2 Mpro has not been reported
(Zhang et al., 2020b). Exogenous CBD administration
has been shown to suppress inflammatory transcription
factors such as AP-1, NF-kB, and NFAT. As a result,
cytokines such as IL-6, IL-1b, IL-1a, GM-CSF, and TNFα
are suppressed in various cells and tissues (Nichols and
Kaplan, 2020). Differentiation of Th17 cells, also shown
to be suppressed by CBD, is promoted by IL-6 (Zgair et
al., 2017). In murine models of chronic asthma, as a result
of CBD administration, cytokine levels of IL-4, IL-5, IL6, IL-13, and TNFα have been shown to decrease, thereby
reducing fibrosis and airway inflammation (Vuolo et al.,
2019). Briefly, these anti-inflammatory effects of CBD
have been proven to be beneficial in administering CBD to
prevent CRS before the inflammatory response becomes
pathological in COVID-19 patients.
3.10. Preclinical evidence of cannabinoid efficacy
Unfortunately, there are limited publications listed on
the effect of CBD on cytokine storm syndrome and acute
respiratory distress syndrome associated with COVID-19.
Until now, a unified treatment regimen for COVID-19 has
not been determined, and most treatments are experimental,
meaning that medications used for other syndromes are
tested on humans (Yagisawa et al., 2021; Sledzinski et
al., 2021). The major cause of the significant morbidity
and high mortality rate associated with the disease is the
lack of specific treatment for COVID-19 (Egmond et al.,
2021). The only treatments available today are represented
by supportive care (Song et al. 2020). Treatment options
contain antivirals, immunoglobulins, antimalarials, IL-6
inhibitors, corticosteroids, immunotherapy, convalescent

plasma, anti-GM-CSF, antibiotics, oxygen therapy, and
circulation support (Song et al., 2020; Vijayvargiya et al.,
2020).
Recently, a large number of studies have been reported,
especially on the possible therapeutic use of cannabinoids
for COVID-19. A partial list of published preclinical
evidence of cannabinoid efficacy in COVID-19 through
some reported observational studies are presented in
Table. The first evidence of the effect of cannabis or seed
extracts on COVID-19 was reported 3 years ago by a
group of Italian researchers (Orio et al., 2017). In their
studies, they showed that the four peptide forms, GVLY,
IEE, LGV, and RVR, prepared from cannabis seeds, have
ACE inhibitory activity. In a recent paper, high-CBD
extracts have been reported to down-regulate TMPRSS2
enzymes and ACE2 and crucial viral gateways in oral,
lung, and intestinal epithelia constituting important
routes of SARS-CoV-2 invasion (Wang et al., 2020). These
authors proposed cannabidiol products for mouthwash
as a preventive strategy in COVID-19 infection to reduce
the entry of SARS-CoV-2 into susceptible hosts by downregulating the enzymes TMPRSS2 and ACE2. After this
study, Esposito et al. (2020) hypothesized that systemic
administration of cannabidiol might have the potential
to limit the progression of COVID-19 disease and postinfection sequelae because cannabidiol may reduce
viral entry by downregulating the TMPRSS2 and ACE2
receptor (Esposito et al., 2020). In line with these studies,
some other researchers hypothesized that CBD could be
useful as an antiviral (Hill, 2020) or anti-inflammatory
(Byrareddy and Mohan, 2020; Costiniuk and Jenabian,
2020) agent for COVID-19. As reported by Huang et
al. (2020), the abnormal release of proinflammatory
molecules and cytokines are closely associated with lung
injury in the SARS-CoV-2 pandemic. Therefore, it is
extremely important that antiviral or other compounds
used for the treatment of COVID 19 prevent the abnormal
release of cytokines and proinflammatory molecules. The
effect of natural cannabinoids in reducing ACE2 activity
has recently been confirmed (Anil et al., 2021). In that
study, CBD, CBG, and THCV fractions were extracted
from a C. sativa strain and tested in vitro with a standard
phytocannabinoid. Both extract fractions of CBD, CBG,
and THCV and the standard phytocannabinoid have been
found to induce polarization of the macrophage cell line
KG1, reduce the secretion of pro-inflammatory cytokines
IL-6, IL-8, CCL2, and CCL7 from the alveolar epithelial
cell line A549, and increase phagocytosis. In that study,
Anil et al. (2021) also reported that the phytocannabinoid
formulation containing cannabidiol limits pulmonary
fibrosis by decreasing the expression levels of ACE2 and
interleukin-7 (IL-7). By decreasing the expression levels
of IL-6 and IL-8, the authors suggested that cannabinoid
compounds have important anti-inflammatory properties
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Table. A partial list of published preclinical evidence of cannabinoid efficacy in COVID-19 through recently reported studies.
Study type

Tested Cannabinoid

Cannabinoid
properties for
COVID-19

Peptides extracted
from seed such as
ACE inhibitory
GVLY, IEE, LGV and activity
RVR

Findings

Peptide forms extracted from hemp
seed had ACE inhibitory activity
preventing the entry of SARS-CoV-2
into cells
13 high CBD / low THC lines were
identified that modulate TMPRSS2
3D tissue models
CBD extracts
Anti-inflammatory
and ACE2 levels to reduce the virus
effect
Decreased levels of interleukin
Lung epithelial cell CBD, THCV, CBG,
Anti-inflammatory; (IL) -6 and -8, Decrease in lung
model
and multiple terpenes Pro-inflammatory
inflammation, Increased IL-6 and
IL-8 expression in macrophages
α-ketoamide,
Using THC and CBD in combination
in vitro and in silico
Antivirals;
THCA,THC, CBN,
with other drugs in the treatment of
approaches
Pro-inflammatory
CBD, CBDA
COVID-19 patients
A549 human
Prevention of SARS- SARS-CoV-2 replication blocked in
CBD and 7-OH-CBD
lung carcinoma cells
CoV-2 replication
lung epithelial cells
Improvement of clinical symptoms
ARDS induced
of ARDS and decrease in
CBD
Anti-inflammatory
by poly(I:C)
proinflammatory cytokine level
caused by Poly I: C
Regulation of apelin
ARDS induced
CBD
level in the blood,
Increase in blood apelin expression
by poly(I:C)
Anti-inflammatory
Human lung
Amplified antiviral
Preventative treatment directly to the
NT-VRL-1 with CBD
fibroblasts
effect
lungs
Pro-inflammatory,
EpiDermFT model
Inhibition of COX-2 and IL-6 levels
Cannabis extracts
Anti-inflammatory,
in WI-38 lung fibroblasts
Anti-fibrotic

ACE-inhibitory
activity test

in lung tissue. In another study where viral infections were
simulated by using synthetic RNA Poly I: C, it was shown
that ARDS induced by Poly I: C could be prevented by
CBD (Khodadadi et al., 2020).
In another preclinical study revealing the positive
potential of CBD for the treatment of COVID-19,
polycytidylic acid poly (I: C), a synthetic analogue of viral
double-stranded RNA, was used in mice to induce ARDS
(Salles et al., 2020). As a result of CBD administration,
parallel to the improvement in the lung structure, T cells
and neutrophils reached their normal levels, along with an
increase in the level of apelin compared to the control. As
plant essential oils, terpenes are the second most abundant
metabolites in hemp after cannabinoids. Glycyrrhizin,
which is also abundant in cannabis plants, has been shown
to have antiviral effects against various SARS-CoV species
(Cinat et al., 2003). In this context, in a recent study on in
vitro evaluation of a mixture of terpene and cannabidiol
activity against human coronavirus E229i, the combination
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Reference

Orio et al., (2017)

Wang et al., (2020)

Anil et al., (2021)

Raj et al., (2021)
Nguyen et al., (2021)
Khodadadi et al., (2021)

Salles et al., (2020)
Chatow et al., (2021)
Kovalchuk et al., (2021)

of NT-VRL-1 (Code-name of terpene-based formulation)
with CBD potentiated the antiviral effect (Chatow et al.,
2021). In parallel, in a recent study it has been hypothesized
that seven novel C. sativa extracts reduce the expression
of pro-inflammatory cytokines and pathways related to
fibrosis and inflammation (Kovalchuk et al., 2021), antiTNFα, and anti-IL-6 cannabis extracts have been shown
to contribute to existing anti-inflammatory regimens
in treating COVID-19. A previous report showed that a
combination of major terpenes and CBD works twice
more than corticosteroids in treating COVID-19, albeit
the final report of this study is still unpublished.3 In
another recent study, cannabidiol has also been proven
to be a stronger antiviral than reference drugs such as
lopinavir, chloroquinone, and remdesivir (Raj et al., 2021).
3
Forbes (2020). New Research Suggests Terpenes And CBD Work
2X’s Better For Covid-19 Inflammation Than Corticosteroid. Website https://www.forbes.com/sites/emilyearlenbaugh [accessed 04
May 2021]
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As a result of this study, it has been shown that cannabidiol
in combination can be used to treat SARS-CoV-2 patients.
In a very recent study with the administration of CBD and
7-OH-CBD to human lung carcinoma cells, SARS-CoV-2
infection in its early stages was likely blocked by 7-OHCBD, the same metabolite included in the CBD treatment
of epilepsy, and, thus, it has been suggested that lower
SARS-CoV-2 infection occurs (Nguyen et al., 2021).
In brief, preclinical studies show that the administration
of CBD through therapeutic interventions has antiviral,
pro-inflammatory, and anti-inflammatory effects on
organs targeted by the coronavirus; these may have been
achieved mainly from the actions of CBD itself, or by
synergistic chemicals such as terpenes that contribute
to this action. Although the exact mechanisms have
not been fully elucidated, several studies have shown
that the endocannabinoid system; the involvement
of endocannabinoids, cannabinoid receptors, and
cannabinoid enzymes is described above.
3.11. Clinical evidence of cannabinoid efficacy
As of May 15, 2021, in the ClinicalTrials.gov database,
there are nine clinical trials (two not yet recruiting, two
active, not recruiting, and five recruiting) on CBD use in
the context of COVID.4 As these studies will take some time
to be completed, numerous other clinical trials have been
reported in the ClinicalTrials.gov database indicating that
CBD, THC, or both, or their synthetic derivatives, could be
used in the prevention of COVID 19 (653 items regarding
cannabinoids; 311 studies were signed as completed, 30
terminated, 151 recruiting, 56 not yet recruiting and 105 of
them withdrawn or unknown or enrolling by invitation).
In the database, contrary to preclinical evidence
of cannabinoid efficacy for COVID-19 (Table), a large
number of clinical trials are underway that will show
their promising effects in the near future. However,
cannabinoids are currently used as anxiolytic, relaxing, and
anti-inflammatory therapeutic agent that can help in cases
of epilepsy, schizophrenia, multiple sclerosis, depression,
or chronic pain. Below, we discuss the details of 5 clinical
studies reported in the database on 3 different pathologies
(reducing pain, seizures, and the spasticity associated
with multiple sclerosis, and fighting seizures of epilepsy in
which cannabinoids are used most. There are seven studies
dedicated to using the cannabinoids such as GW-1000-02
(THC) or CBD or Drug: Nabiximols (Sativex) (cannabis
extract containing THC+CBD) in patients with painrelated symptoms, including the study entitled “Sativex
for relieving persistent pain in participants with advanced
cancer” (daily doses of 100 microliters (μL) oromucosal
spray (2.5 mg CBD and 2.7 mg THC) in the evening and
morning, up to a maximum of 10 sprays per day, for 5
ClinicalTrials.gov (2021). U.S. National Library of Medicine. COVID-19 Information Dashboard [online]. Website https://www.ncbi.
nlm.nih.gov/sars-cov-2/[accessed 15 May 2021]
4

weeks) and the study entitled “A two-part study of Sativex
oromucosal spray for relieving uncontrolled persistent
pain in patients with advanced cancer” (Nabiximols
oromucosal spray contained CBD (25 mg/mL) and
THC (27 mg/mL, for 5 weeks). Forty-eight studies (21
completed) are dedicated to the use of cannabinoids mostly
cannabidiol or its derivatives such as Epidiolex (formerly,
GWP42003-P) in patients with childhood epilepsy,
including the study entitled “Antiepileptic efficacy study
of GWP42003-P in children and young adults with dravet
syndrome (GWPCARE1)” (A daily dose of 20 mg/kg/day
for 11 days and this dose should be used for 12 weeks) and
the study entitled “Efficacy and safety of GWP42003-P
for seizures associated with Lennox-Gastaut syndrome
in children and adults” with a daily dose of 10 and 20 mg
(mg) per kilogram (kg) per day (mg/kg/day). Twenty-five
studies (17 completed) are dedicated to the use of drug:
Sativex, drug: GW-1000-02 or cannabis extract containing
THC+CBD in the spasticity and seizures associated with
multiple sclerosis, including the clinical study entitled
“Sativex versus placebo when added to existing treatment
for central neuropathic pain in MS” (with a daily dose
of 8-12 sprays, each actuation contains 2.7 mg THC and
2.5 mg CBD). These clinical studies demonstrating the
potential therapeutic properties of cannabinoids indicate
that CBD or THC or their synthetic derivatives could also
be used in the treatment of COVID-19 related disorders.
Although clinical trials on COVID-19 are in their infancy,
the following clinical studies have demonstrated that there
are therapeutic effects of CBD on chronic pain (Capano
et al., 2020), respiratory illnesses (Abdallah et al., 2018),
inflammation-related disorders (Couch et al., 2019),
anxiolytic properties (Zuardi et al., 2017), anxiety and sleep
(Shannon et al., 2019), chronic schizophrenia (Boggs et al.,
2018). Therefore, CBD alone or in combination with THC
can be used as an adjuvant therapy to improve the quality
of life of patients with COVID-19 and even to reduce the
stress symptoms that may develop after recovery.
4. Conclusion and future perspectives
Of the many coronavirus strains (SARS, MERS and COVID
19) observed over the last nearly two decades, COVID-19
has been the deadliest Coronavirus pandemic in human
history. The duration and effectiveness of vaccines against
SARS-CoV-2 cannot be predicted yet. In this context,
the use of cannabis cannabinoids, especially CBD alone
as a non-psychoactive cannabinoid or in combination
with THC or terpenes, to limit or stop the severity of the
disease based on reported incentive preclinical studies, in
addition to existing vaccines, should be carefully studied
to achieve protection against COVID-19. However, more
evidence is needed for the routine use of cannabinoids
and particularly non-psychoactive CBD in the treatment
of COVID-19. Therefore, we hope that our hypothesis,
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supported by a large number of preclinical evidence
and continuous clinical trial results, will inspire further
targeted clinic studies to offer natural treatment options
or the development of a broad spectrum medication for
coronaviruses including SARS-CoV-2 responsible for
COVID-19.

Conflict of interest
The authors declare that there is no conflict of interest.
Acknowledgment
We would like to thank Mr. İbrahim TÜNİK for his
invaluable linguistic corrections.

References
Abdallah SJ, Smith BM, Ware MA, Moore M, Li PZ et al. (2018).
Effect of vaporized cannabis on exertional breathlessness
and exercise endurance in advanced chronic obstructive
pulmonary disease. A randomized controlled trial. Annals
of the American Thoracic Society 15 (10): 1146-1158. doi:
10.1513/AnnalsATS.201803-198OC
Abian O, Ortega-Alarcon D, Jimenez-Alesanco A, Ceballos-Laita
L, Vega S et al. (2020). Structural stability of SARS-CoV-2
3CLpro and identification of quercetin as an inhibitor
by experimental screening. International Journal of
Biological Macromolecules 164: 1693-1703. doi: 10.1016/j.
ijbiomac.2020.07.235
Alhouayek
M,
Muccioli
GG
(2014).
COX-2derived endocannabinoid metabolites as novel
inflammatorymediators. Trends in Pharmacological
Sciences 35 (6): 284-92. doi: 10.1016/j.tips.2014.03.001
Al-Khafaji K, Al-Duhaidahawi D, Taskin TT (2020). Using
integrated computational approaches to identify safe and
rapid treatment for SARS-CoV-2. Journal of Biomolecular
Structure and Dynamics 39 (9): 3387-3395. doi:
10.1080/07391102.2020.1764392
Almada M, Alves P, Fonseca BM, Carvalho F, Queiros CR et al.
(2020). Synthetic cannabinoids JWH-018, JWH-122, UR144 and the phytocannabinoid THC activate apoptosis
in placental cells. Toxicology Letters 319: 129-137. doi:
10.1016/j.toxlet.2019.11.004
Almogi-Hazan O, Or R (2020). Cannabis, the endocannabinoid
system and immunity-the journey from the bedside to
the bench and back. International Journal of Molecular
Sciences 21 (12): 4448. doi: 10.3390/ijms21124448
Anil SM, Shalev N, Vinayaka AC, Nadarajan S, Namdar D et al.
(2021). Cannabis compounds exhibit anti-inflammatory
activity in vitro in COVID-19-related inflammation in
lung epithelial cells and pro-inflammatory activity in
macrophages. Scientific Reports 11: 1462. doi: 10.1038/
s41598-021-81049-2
Apostu D, Lucaciu O, Mester A, Benea H, Oltean-Dan D
et al. (2019). Cannabinoids and bone regeneration.
Drug Metabolism Reviews 51 (1): 65-75. doi:
10.1080/03602532.2019.1574303
Badowski ME, Yanful PK (2018). Dronabinol oral solution in
the management of anorexia and weight loss in AIDS and
cancer. Therapeutics and Clinical Risk Management 14:
643-651. doi: 10.2147/TCRM.S126849

582

Baggelaar MP, Maccarrone M, Van der Stelt M (2018).
2-Arachidonoylglycerol: a signaling lipid with manifold
actions in the brain. Progress in Lipid Research 71: 1-17.
doi: 10.1016/j.plipres.2018.05.002
Bian J, Li Z (2021). Angiotensin-converting enzyme 2
(ACE2): SARS-CoV-2 receptor and RAS modulator.
Acta Pharmaceutica Sinica B 11 (1): 1-12. doi: 10.1016/j.
apsb.2020.10.006
Boechat JL, Chora I, Morais A, Delgado L (2021). The
immune response to SARS-CoV-2 and COVID-19
immunopathology–current perspectives (in press).
Pulmonology doi: 10.1016/j.pulmoe.2021.03.008
Boggs DL, Surti T, Gupta A, Gupta S, Niciu M et al. (2018). The
effects of cannabidiol (CBD) on cognition and symptoms
in outpatients with chronic schizophrenia a randomized
placebo controlled trial. Psychopharmacology 235 (7):
1923-1932. doi: 10.1007/s00213-018-4885-9
Burki T (2021). Understanding variants of SARS-CoV-2.
The Lancet 397 (10273): 462. doi: 10.1016/S01406736(21)00298-1
Burstein S (2015). Cannabidiol (CBD) and its analogs: a
review of their effects on inflammation. Bioorganic and
Medicinal Chemistry 23 (7): 1377-1385. doi: 10.1016/j.
bmc.2015.01.059
Byrareddy SN, Mohan M (2020). SARS-CoV-2 induced
respiratory distress: Can cannabinoids be added to anti-viral
therapies to reduce lung inflammation? Brain, Behavior,
and Immunity 87: 120-121. doi: 10.1016/j.bbi.2020.04.079
Cabral GA, Griffin-Thomas
cannabinoid receptor
therapeutic prospects
Reviews in Molecular
S1462399409000957

L (2009). Emerging role of the
CB2 in immune regulation:
for neuroinflammation. Expert
Medicine 11: e3. doi: 10.1017/

Capano A, Weaver R, Burkman E (2020). Evaluation of the
effects of CBD hemp extract on opioid use and quality of
life indicators in chronic pain patients: a prospective cohort
study. Postgraduate Medicine 132 (1): 56-61. doi:10.1080/0
0325481.2019.1685298
Chatow L, Nudel A, Nesher I, Hayo-Hemo D, Rozenberg P et al.
(2021). In vitro evaluation of the activity of terpenes and
cannabidiol against human coronavirus E229. Life 11 (4):
290. doi: 10.3390/life11040290

ONAY et al. / Turk J Biol
Cinat J, Morgenstern B, Bauer G, Chandra P, Rabenau H et al.
(2003). Glycyrrhizin, an active component of liquorice roots
and replication of SARS-associated coronavirus. The Lancet
361: 2045–2046. doi: 10.1016/S0140-6736(03)13615-X
Cohen K, Weinstein A (2018). The effects of cannabinoids on
executive functions: evidence from cannabis and synthetic
cannabinoids-a systematic review. Brain Sciences 8 (3): 40.
doi: 10.3390/brainsci8030040
Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R et al.
(2020). Induction of pro-inflammatory cytokines (IL-1 and
IL-6) and lung inflammation by Coronavirus-19 (COVI-19
or SARS-CoV-2): anti-inflammatory strategies. Journal of
Biological Regulators and Homeostatic Agents 34 (2): 1.
doi: 10.23812/CONTI-E
Costiniuk CT, Jenabian MA (2020). Acute inflammation and
pathogenesis of SARS-CoV-2 infection: Cannabidiol
as a potential anti-inflammatory treatment?. Cytokine
and Growth Factor Reviews 53: 63-65. doi: 10.1016/j.
cytogfr.2020.05.008
Costiniuk CT, Saneei Z, Routy J, Margolese S, Mandarino E et
al. (2019). Oral cannabinoids in people living with HIV on
effective antiretroviral therapy: CTN PT028- study protocol
for a pilot randomised trial to assess safety, tolerability and
effect on immune activation. BMJ Open 9 (1): e024793. doi:
10.1136/bmjopen-2018-024793
Couch DG, Cook H, Ortori C, Barrett D, Lund JN et al.
(2019). Palmitoylethanolamide and cannabidiol prevent
inflammation-induced hyperpermeability of the human
gut in vitro and in vivo—a randomized, placebo-controlled,
double-blind controlled trial. Inflammatory Bowel Diseases
25 (6): 1006-1018. doi: 10.1093/ibd/izz017
Desai AN, Patel P (2020). Stopping the spread of COVID-19.
The Journal of the American Medical Association 323 (15):
1516-1516. doi: 10.1001/jama.2020.4269
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA et
al. (1992). Isolation and structure of a brain constituent
that binds to the cannabinoid receptor. Science 258 (5090):
1946-1949. doi: 10.1126/science.1470919
Dujourdy L, Besacier F (2017). A study of cannabis potency
in France over a 25 years period (1992–2016). Forensic
Science International 272: 72-80. doi: 10.1016/j.
forsciint.2017.01.007
Ebbert JO, Scharf EL, Hurt RT (2018). Medical cannabis. Mayo
Clinic Proceedings 93 (12): 1842-1847. doi: 10.1016/j.
mayocp.2018.09.005
Egmond NV, Straub VM, Der Stelt MV (2021). Targeting
endocannabinoid signaling: FAAH and MAG lipase
inhibitors. Annual Review of Pharmacology and
Toxicology 61: 441-463. doi: 10.1146/annurevpharmtox-030220-112741
Eisenstein TK, Meissler JJ, Wilson Q, Gaughan JP, Adler MW
(2007). Anandamide and Δ9-tetrahydrocannabinol directly
inhibit cells of the immune system via CB2 receptors.
Journal of Neuroimmunology 189 (1-2): 17-22. doi:
10.1016/j.jneuroim.2007.06.001

El Biali M, Broers B, Besson M, Demeules J (2020). Cannabinoids
and COVID-19. Medical Cannabis and Cannabinoids 3 (2):
111-115. doi: 10.1159/000510799
El-Sayed A, Kamel M (2021). Coronaviruses in humans and
animals: the role of bats in viral evolution. Environmental
Science and Pollution Research 28: 19589-19600 doi:
10.1007/s11356-021-12553-1
Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J et al. (2020).
The potential of cannabidiol in the COVID‐19 pandemic.
British Journal of Pharmacology 177 (21): 4967-4970. doi:
10.1111/bph.15157
Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB,
Rice AS et al. (2000). Cannabinoid CB1 receptor expression
in rat spinal cord. Molecular and Cellular Neuroscience 15:
510-521. doi: 10.1006/mcne.2000.0844
Feliu A, Moreno‐Martet M, Mecha M, Carrillo‐Salinas FJ,
De Lago E et al. (2015). A Sativex®‐like combination of
phytocannabinoids as a disease‐modifying therapy in
a viral model of multiple sclerosis. British Journal of
Pharmacology 172: 3579-3595. doi: 10.1111/bph.13159
Gadanec LK, McSweeney KR, Qaradakhi T, Ali B, Zulli A et
al. (2021). Can SARS-CoV-2 virus use multiple receptors
to enter host cells?. International Journal of Molecular
Sciences 22 (3): 992. doi: 10.3390/ijms22030992
Gaoni Y, Mechoulam R (1964). Isolation, structure, and partial
synthesis of an active constituent of hashish. Journal of
the American Chemical Society 86 (8): 1646-1647. doi:
10.1021/ja01062a046
Ghaffari S, Roshanravan N, Tutunchi H, Ostadrahimi A,
Pouraghaei M et al. (2020). Oleoylethanolamide, a
bioactive lipid amide, as a promising treatment strategy for
coronavirus/COVID-19. Archives of Medical Research 51
(5): 464-467. doi: 10.1016/j.arcmed.2020.04.006
Greenberg DA (2003). Endocannabinoids. In: Aminoff MJ,
Daroff RB (editors). Encyclopedia of the Neurological
Sciences. New York, NY, USA: Academic Press, pp. 143-144
Han Y, Kral P (2020). Computational design of ACE2-based
peptide inhibitors of SARS-CoV-2. ACS Nano 14 (4): 51435147. doi: 0.1021/acsnano.0c02857
Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z et al. (2001).
2-Arachidonyl glyceryl ether, an endogenous agonist of
the cannabinoid CB1 receptor. Proceedings of the National
Academy of Sciences 98 (7): 3662-3665. doi: 10.1073/
pnas.061029898
Hernandez-Cervantes R, Mendez-Diaz M, Prospero-Garcia
O, Morales-Montor J (2017). Immunoregulatory
role of cannabinoids during infectious disease.
Neuroimmunomodulation 24 (4-5): 183-199. doi:
10.1159/000481824
Hill KP (2020). Cannabinoids and the coronavirus. Cannabis
and Cannabinoid Research 5 (2): 118–120. doi: 10.1089/
can.2020.0035

583

ONAY et al. / Turk J Biol
Howlett AC, Abood MC (2017). CB1 & CB2 Receptor
Pharmacology. Advances in Pharmacology 80: 169–206.
doi: 10.1016/bs.apha.2017.03.007
Hu TY, Frieman M, Wolfram J (2020). Insights from nanomedicine
into chloroquine efficacy against COVID-19. Nature
Nanotechnology 15 (4): 247-249. doi: 10.1038/s41565-0200674-9
Huang C, Wang Y, Li X, Ren L., Zhao J et al. (2020). Clinical
features of patients infected with 2019 novel coronavirus
in Wuhan, China. The Lancet 395 (10223): 497-506. doi:
10.1016/S0140-6736(20)30183-5
Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis
L et al. (2002). An endogenous capsaicin-like substance
with high potency at recombinant and native vanilloid VR1
receptors. Proceedings of the National Academy of Sciences
99 (12): 8400-8405. doi: 10.1073/pnas.122196999
Hui DS, Lee N, Chan PK, Beigel JH (2018). The role of adjuvant
immunomodulatory agents for treatment of severe
influenza. Antiviral Research 150: 202-216. doi: 10.1016/j.
antiviral.2018.01.002
Li HL (1974). An archaeological and historical account of
cannabis in China. Economic Botany, 28 (4), 437-448.
Published by: Springer on behalf of New York Botanical
Garden Press
Iannotti FA, Vitale RM (2021). The endocannabinoid system
and PPARs: Focus on their signalling crosstalk, action and
transcriptional regulation. Cells 10 (3): 586. doi: 10.3390/
cells10030586
Karmous PWF, Gagner JG, Harkema JK, Kaminski NE, Kaplan BLF
(2013). Cannabidiol (CBD) enhances lipopolysaccharide
(LPS)-induced pulmonary inflammation in C57BL/6
mice. Journal of Immunotoxiclogy 10 (3): 321-328. doi:
10.3109/1547691X.2012.741628
Kapellos TS, Taylor L, Feuerborn A, Valaris S, Hussain MT,
Rainger GE, Greaves DR, Iqbal AJ (2019). Cannabinoid
receptor 2 deficiency exacerbates inflammation and
neutrophil recruitment. The FASEB Journal 33: 6154-6167.
doi.org/10.1096/fj.201802524R
Khodadadi H, Salles EL, Jarrahi A, Chibane F, Costigliola V et
al. (2020). Cannabidiol modulates cytokine storm in acute
respiratory distress syndrome induced by simulated viral
infection using synthetic RNA. Cannabis and Cannabinoid
Research 5 (3): 197-201. doi: 10.1089/can.2020.0043
Khuja I, Yekhtin Z, Or R, Almogi-Hazan O (2018). Cannabinoids
reduce inflammation but inhibit lymphocyte recovery
in murine models of bone marrow transplantation.
International Journal of Molecular Sciences 20 (3): 668.
doi:10.3390/ijms20030668
Kovalchuk A, Wang B, Li D, Rodriguez-Juarez R, Ilnytskyy S
et al. (2021). Fighting the storm: could novel anti-TNFα
and anti-IL-6 C. sativa cultivars tame cytokine storm in
COVID-19?. Aging (Albany NY) 13 (2): 1571–1590. doi:
10.18632/aging.202500

584

Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE et al. (2002).
15-Lipoxygenase metabolism of 2-arachidonylglycerol:
Generation of a peroxisome proliferator-activated receptor
α agonist. Journal of Biological Chemistry, 277 (26): 2327823286. doi: 10.1074/jbc.M201084200
Kozak KR, Rowlinson SW, Marnett LJ (2000). Oxygenation
of the endocannabinoid, 2-arachidonylglycerol, to
glyceryl prostaglandins by cyclooxygenase-2. Journal of
Biological Chemistry 275 (43): 33744–49. doi: 10.1074/jbc.
M007088200
Kumar A, Premoli M, Aria F, Bonini SA, Maccarinelli G
et al. (2019). Cannabimimetic plants: are they new
cannabinoidergic modulators?. Planta 249 (6): 1681-1694.
doi: 10.1007/s00425-019-03138-x
Laezza C, Pagano C, Navarra G, Pastorino O, Proto MC et al.
(2020). The endocannabinoid system: A target for cancer
treatment. International Journal of Molecular Sciences 21
(3): 747. doi: 10.3390/ijms21030747
Lauritsen KJ, Rosenberg H (2016). Comparison of outcome
expectancies for synthetic cannabinoids and botanical
marijuana. The American Journal of Drug and Alcohol
Abuse 42 (4): 377-384. doi: 10.3109/00952990.2015.1135158
Li X, Hua T, Vemuri K, Ho JH, Wu Y et al. (2019). Crystal
structure of the human cannabinoid receptor CB2. Cell 176
(3): 459-467. doi: 10.1016/j.cell.2018.12.011
Li HL (1974). The origin and use of Cannabis in Eastern Asia
linguistic-cultural implications. Economic Botany 28 (3):
293-301. doi: 10.1007/BF02861426
Lima EMG, Tardelli VS, Brietzke E, Fidalgo TM (2021). Cannabis
and inflammatory mediators. European Addiction Research
27 (1): 16-24. doi: 10.1159/000508840
Liu DX, Liang JQ, Fung TS (2021). Human Coronavirus-229E,
-OC43, -NL63, and -HKU1 (Coronaviridae). Encyclopedia
of Virology (Fourth Edition) 2: 428-440. doi: 10.1016/
B978-0-12-809633-8.21501-X
Lowe R, Wu Y, Tamar A, Harb J, Abbeel P, Mordatch I (2017).
Multi agent actor critic for mixed cooperative competitive
environments. 31st Conference on Neural Information
Processing Systems (NIPS 2017) 6382–6393 Long Beach,
CA, USA.
Lu HC, Mackie K (2016). An introduction to the endogenous
cannabinoid system. Biological Psychiatry 79 (7): 516-525.
doi: 10.1016/j.biopsych.2015.07.028
Lucaciu O, Aghiorghiesei O, Petrescu NB, Mirica IC, Benea HRC
et al. (2021). In quest of a new therapeutic approach in
COVID-19: the endocannabinoid system. Drug Metabolism
Reviews (in press). doi: 10.1080/03602532.2021.1895204
Maor Y, Yu J, Kuzontkoski PM, Dezube BJ, Zhang X et al. (2012).
Cannabidiol inhibits growth and induces programmed cell
death in kaposi sarcoma–associated herpesvirus-infected
endothelium. Genes and Cancer 3 (7-8): 512-520. doi:
10.1177/1947601912466556

ONAY et al. / Turk J Biol
Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford
JL, Shriver LP, Ledent C et al. (2007). Direct suppression
of CNS autoimmune inflammation via the cannabinoid
receptor CB1 on neurons and CB2 on autoreactive T cells.
Nature Medicine 13 (4): 492-497. doi: 10.1038/nm1561

Nagarkatti P, Miranda K, Nagarkatti M (2020). Use of
Cannabinoids to Treat Acute Respiratory Distress Syndrome
and Cytokine Storm Associated with Coronavirus
Disease-2019. Frontiers in Pharmacology 11: 589438. doi:
10.3389/fphar.2020.589438

Martinez V, Iriondo De-Hond A, Borrelli F, Capasso R, Del
Castillo MD et al. (2020). Cannabidiol and other nonpsychoactive cannabinoids for prevention and treatment
of gastrointestinal disorders: Useful nutraceuticals?.
International Journal of Molecular Sciences 21 (9): 3067.
doi: 10.3390/ijms21093067

Nguyen LC, Yang D, Nicolaescu V, Best T, Chen S et al.
(2021). Cannabidiol inhibits SARS-CoV-2 replication
and promotes the host innate immune response. The
Preprint Server for Biology (bioRxiv) (In Press). doi:
10.1101/2021.03.10.432967

Mastinu A, Premoli M, Ferrari-Toninelli G, Tambaro S,
Maccarinelli G et al. (2018). Cannabinoids in health and
disease: Pharmacological potential in metabolic syndrome
and neuroinflammation. Hormone Molecular Biology
and Clinical Investigation, 20180013. doi: 10.1515/hmbci
-2018-0013
Mecha M, Feliu A, Inigo PM, Mestre L, Carrillo-Salinas FJ, et
al. (2013). Cannabidiol provides long-lasting protection
against the deleterious effects of inflammation in a viral
model of multiple sclerosis: a role for A2A receptors.
Neurobiology of Disease 59: 141-150. doi: 10.1016/j.
nbd.2013.06.016
Mechoulam R, Peters M, Murillo‐Rodriguez E, Hanus LO (2007).
Cannabidiol-recent advances. Chemistry and Biodiversity
4 (8): 1678-1692. doi: 10.1002/cbdv.200790147
Mills B, Yepes A, Nugent K (2015). Synthetic cannabinoids. The
American Journal of the Medical Sciences 350 (1): 59-62.
doi: 10.1097/MAJ.0000000000000466
Mohammed A, Alghetaa HK, Zhou J, Chatterjee S, Nagarkatti P
et al. (2020). Protective effects of Δ9‐tetrahydrocannabinol
against enterotoxin‐induced acute respiratory distress
syndrome are mediated by modulation of microbiota.
British Journal of Pharmacology 177 (22): 5078-5095. doi:
10.1111/bph.15226
Molaei S, Dadkhah M, Asghariazar V, Karami C, Safarzadeh
E (2020). The immune response and immune evasion
characteristics in SARS-CoV, MERS-CoV, and SARSCoV-2: Vaccine design strategies. International
Immunopharmacology 92: 107051. doi: 10.1016/j.
intimp.2020.107051

Nichols JM, Kaplan BLF (2020). Immune responses regulated by
cannabidiol. Cannabis and Cannabinoid Research 5: 12–31.
doi:10.1089/can.2018.0073
Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey
SG, Marcondes MCG et al. (2011). Endocannabinoid
hydrolysis generates brain prostaglandins that promote
neuroinflammation. Science, 334 (6057): 809-813.
doi:10.1126/science.1209200
Olah A, Szekanecz Z, Biro T (2017). Targeting Cannabinoid
Signaling in the Immune System: “High”-ly Exciting
Questions, Possibilities, and Challenges. Frontiers in
Immunology 8:1487. doi.org/10.3389/fimmu.2017.01487
Onaivi ES, Sharma V (2020). Cannabis for COVID-19: can
cannabinoids quell the cytokine storm?. Future Science OA
6 (8): FSO625. doi:10.2144/fsoa-2020-0124
Orio LP, Boschin G, Recca T, Morelli CF, Ragona L et al.
(2017). New ACE-inhibitory peptides from hemp seed
(Cannabis sativa L.) proteins. Journal of Agricultural and
Food Chemistry 65 (48): 10482–10488. doi: 10.1021/acs.
jafc.7b04522
Paland N, Pechkovsky A, Aswad M, Hamza H, Popov T et al.
(2021). The immunopathology of COVID-19 and the
Cannabis Paradigm. Frontiers in Immunology 12: 327. doi:
10.3389/fimmu.2021.631233
Paloczi J, Matyas C, Cinar R, Varga ZV, Hasko G et al. (2019).
Alcohol binge-induced cardiovascular dysfunction involves
endocannabinoid–CB1-R signaling. Basic to Translational
Science 4 (5): 625-637. doi: org/j.jacbts.2019.05.007
Parks JM, Smith JC (2020). How to discover antiviral drugs
quickly. New England Journal of Medicine 382 (23): 22612264. doi: 10.1056/NEJMcibr2007042

Moran MM, McAlexander MA, Biro T, Szallasi A (2011).
Transient receptor potential channels as therapeutic targets.
Nature Reviews Drug Discovery 10: 601-620. doi: 10.1038/
nrd3456

Pereira JP, An J, Xu Y, Huang Y, Cyster JG (2009). Cannabinoid
receptor 2 mediates the retention of immature B cells in
bone marrow sinusoids. Nature Immunology 10 (4):403411. doi: 10.1038/ni.1710

Morrison AR, Johnson JP, Griebe KM, Stine JJ, Hencken LN, To
L, Bianchini ML et al. (2020). Clinical characteristics and
predictors of survival in adults with coronavirus disease
2019 receiving tocilizumab. Journal of Autoimmunity 114:
102512. doi: 10.1016/j.jaut.2020.102512

Pertwee RG (2010). Receptors and channels targeted by
synthetic cannabinoid receptor agonists and antagonists.
Current Medicinal Chemistry 17 (14): 1360-1381. doi:
10.2174/092986710790980050

Nachnani R, Raup-Konsavage WM, Vrana KE (2021). The
pharmacological case for cannabigerol. Journal of
Pharmacology and Experimental Therapeutics 376 (2):
204-212. doi: 10.1124/jpet.120.000340

Pertwee RG, Howlett, AC, Abood ME, Alexander SPH, Di Marzo
V et al. (2010). International union of basic and clinical
pharmacology. LXXIX. Cannabinoid receptors and their
ligands: Beyond CB1 and CB2. Pharmacological Reviews
62 (4): 588-631. doi: 10.1124/pr.110.003004

585

ONAY et al. / Turk J Biol
Petrescu NB, Jurj A, Soritau O, Lucaciu OP, Dirzu N, Raduly
L et al. (2020). Cannabidiol and Vitamin D3 Impact on
Osteogenic Differentiation of Human Dental Mesenchymal
Stem Cells. Medicana (Kaunas) 56 (11): 607. doi: 10.3390/
medicina56110607
Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R,
Cuomo G, Abate M, Faggiana G et al. (2017). Cannabidiol:
State of the art and new challenges for therapeutic
applications. Pharmacology and Therapeutics 175: 133150. doi: 10.1016/j.pharmthera.2017.02.041.
Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ et
al. (2002). Characterization of a novel endocannabinoid,
virodhamine, with antagonist activity at the CB1 receptor.
Journal of Pharmacology and Experimental Therapeutics
301 (3): 1020-1024. doi: 10.1124/jpet.301.3.1020
Raj V, Park JG, Cho KH, Choi P, Kim T et al. (2021). Assessment
of antiviral potencies of cannabinoids against SARS-CoV-2
using computational and in vitro approaches. International
Journal of Biological Macromolecules 168: 474-485. doi:
10.1016/j.ijbiomac.2020.12.020
Reiss

CS (2010). Cannabinoids and viral infections.
Pharmaceuticals 3 (6): 1873-1886. doi: 10.3390/ph3061873

Rohbeck E, Eckel J, Romacho T (2021). Cannabinoid receptors in
metabolic regulation and diabetes. Physiology 36 (2): 102113. doi: 10.1152/physiol.00029.2020
Romano M, Ruggiero A, Squeglia F, Maga G, Berisio R (2020).
A structural view of SARS-CoV-2 RNA replication
machinery: RNA synthesis, proofreading and final capping.
Cells 9 (5): 1267. doi: 10.3390/cells9051267
Rossi F, Tortora C, Argenziano M, Di Paola A, Punzo F
(2020). Cannabinoid receptor type 2: A possible target
in SARS-CoV-2 (CoV-19) infection?. International
Journal of Molecular Sciences 21 (11): 3809. doi: 10.3390/
ijms21113809
Salles EL, Khodadadi H, Jarrahi A, Ahluwalia M, Paffaro Jr VA
et al. (2020). Cannabidiol (CBD) modulation of apelin in
acute respiratory distress syndrome. Journal of Cellular and
Molecular Medicine 24 (21): 12869-12872. doi: 10.1111/
jcmm.15883
Schlag AK, Hindocha C, Zafar R, Nutt DJ, Curran HV (2021).
Cannabis based medicines and cannabis dependence:
A critical review of issues and evidence. Journal of
Psychopharmacology doi: 10.1177/0269881120986393
Shamran H, Singh NP, Zumbrun EE, Murphy A, Taub DD, Mishra
MK et al. (2017). Fatty acid amide hydrolase (FAAH)
blockade ameliorates experimental colitis by altering
microRNA expression and suppressing inflammation.
Brain, Behavior, and Immunity 59: 10–20. doi: 10.1016/j.
bbi.2016.06.008
Shannon S, Lewis N, Lee H, Hughes S (2019). Cannabidiol in
anxiety and sleep: A large case series. The Permanente
Journal 23: 18-41. doi: 10.7812/TPP/18-041

586

Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R (2020).
COVID-19 infection: Origin, transmission, and
characteristics of human coronaviruses. Journal of Advanced
Research 24: 91-98. doi: 10.1016/j.jare.2020.03.005
Sledzinski P, Nowak-Terpiłowska A, Zeyland J (2021).
Cannabinoids in medicine: Cancer, immunity, and
microbial diseases. International Journal of Molecular
Sciences 22: 263. doi: 10.3390/ijms22010263
Small E (1979). The species problem in Cannabis: science and
semantics-v. 1: Science.-v. 2: Semantics.
Snider NT, Walker VJ, Hollenberg PF (2010). Oxidation of the
endogenous cannabinoid arachidonoyl ethanolamide by
the cytochrome P450 monooxygenases: physiological and
pharmacological implications. Pharmacological Reviews
62 (1): 136-154. doi: 10.1124/pr.109.001081
Soliman N, Haroutounian H, Hohmann A, Krane E, Liao J et al.
(2021). A systematic review and meta-analysis of cannabisbased medicines, cannabinoids and endocannabinoid
system modulators tested for antinociceptive effects in
animal models of injury-related or pathological persistent
pain. Pain (In Press). doi: 10.1097/j.pain.0000000000002269
Song Y, Zhang M, Yin L, Wang K, Zhou Y et al. (2020).
COVID-19 treatment: close to a cure? A rapid review of
pharmacotherapies for the novel coronavirus (SARSCoV-2). International Journal of Antimicrobial Agents 56
(2): 106080 doi: 10.1016/j.ijantimicag.2020.106080
Stella N, Schweitzer P, Piomelli D (1997). A second endogenous
cannabinoid that modulates long-term potentiation. Nature
388 (6644): 773-778. doi: 10.1038/42015
Storozhuk MV, Zholos AV (2018). TRP channels as novel targets
for endogenous ligands: focus on endocannabinoids and
nociceptive signalling. Current Neuropharmacology 16 (2):
137-150. doi: 10.2174/1570159X15666170424120802
Tahamtan A, Tavakoli-Yaraki M, Rygel TP, Mokhtari-Azad T,
Salimi V (2016). Effects of cannabinoids and their receptors
on viral infections. Journal of Medical Virology 88 (1):
1-12. doi.org/10.1002/jmv.24292
Tay MZ, Poh CM, Renia L, Macary PA, Ng LFP (2020). The trinity
of COVID-19: immunity, inflammation and intervention.
Nature Reviews Immunology 20: 363-374. doi.org/10.1038/
s41577-020-0311-8
Turcotte C, Blanchet MR, Laviotte M, Flamand N (2016). Impact
of Cannabis, Cannabinoids, and Endocannabinoids in the
Lungs. Frontiers in Pharmacology 7: 317. doi: 10.3389/
fphar.2016.00317
Vabret N, Britton GJ, Gruber C, Hegde S, Kim J et al. (2020).
Immunology of COVID-19: current state of the
science. Immunity 52 (6): 910-941. doi: 10.1016/j.
immuni.2020.05.002
Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram
PR, Stevens RW et al. (2020). Treatment considerations
for COVID-19: A critical review of the evidence (or lack
thereof). Mayo Clinic Proceedings 95 (7): 1454-1466. doi:
10.1016/j.mayocp.2020.04.027

ONAY et al. / Turk J Biol
Vuolo F, Abreu SC, Michels M, Xisto DG, Blanco NG et al.
(2019). Cannabidiol reduces airway inflammation and
fibrosis in experimental allergic asthma. European
Journal of Pharmacology 843: 251-259. doi: 10.1016/j.
ejphar.2018.11.029
Wang B, Kovalchuk A, Li D, Ilnytskyy Y, Kovalchuk I et al. (2020). In
Search of Preventative Strategies: Novel Anti-Inflammatory
High-CBD Cannabis sativa Extracts Modulate ACE2
Expression in COVID-19 Gateway Tissues. Preprints
2020040315. doi: 10.20944/preprints202004.0315.v1
Watson CWM, Paolillo EW, Morgan EE, Umlauf A, Sundermann
EE et al. (2020). Cannabis exposure is associated with
a lower likelihood of neurocognitive impairment in
people living with HIV. Journal of Acquired Immune
Deficiency Syndromes 83 (1): 56-64. doi: 10.1097/
QAI.0000000000002211
Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS et al. (2004).
Plasma inflammatory cytokines and chemokines in severe
acute respiratory syndrome. Clinical and Experimental
Immunology 136 (1): 95-103. doi: 10.1111/j.13652249.2004.02415.x
Yagisawa M, Foster PJ, Hanaki H, Omura S (2021). Global trends
in clinical studies of ivermectin in COVID-19. The Japanese
Journal of Antibiotics 74: 1. Access link:161/74-1_44-95
Yang H, Zhou J, Lehmann C (2016). GPR55–a putative “type 3”
cannabinoid receptor in inflammation. Journal of Basic and
Clinical Physiology and Pharmacology 27: 297-302. doi:
10.1515/jbcpp-2015-0080

Yang X, Yu Y, Xu J, Shu H, Liu H et al. (2020). Clinical
course and outcomes of critically ill patients with
SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. The Lancet
Respiratory Medicine 8 (5): 475-481. doi: 10.1016/S22132600(20)30079-5
Zgair A, Lee JB, Wong JC, Taha DA, Aram J et al. (2017). Oral
administration of cannabis with lipids leads to high levels
of cannabinoids in the intestinal lymphatic system and
prominent immunomodulation. Scientific Reports 7 (1):
1-12. doi: 10.1038/s41598-017-15026-z
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020a).
Angiotensin-converting enzyme 2 (ACE2) as a SARSCoV-2 receptor: molecular mechanisms and potential
therapeutic target. Intensive Care Medicine 46 (4): 586-590.
doi: 10.1007/s00134-020-05985-9
Zhang L, Lin D, Sun X, Curth U, Drosten C et al. (2020b). Crystal
structure of SARS-CoV-2 main protease provides a basis
for design of improved α-ketoamide inhibitors. Science 368
(6489): 409-412. doi: 10.1126/science.abb3405
Zou S, Kumar U (2018). Cannabinoid receptors and the
endocannabinoid system: signaling and function in the
central nervous system. International Journal of Molecular
Sciences 19 (3): 833. doi: 10.3390/ijms19030833
Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JE et
al. (2017). Inverted U-shaped dose-response curve of the
anxiolytic effect of cannabidiol during public speaking in
real life. Frontiers in Pharmacology 8: 259. doi: 10.3389/
fphar.2017.00259

587

